Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0023418 (leukemia)
 93,477 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl) uracil (BV-ara-U) and 1-beta-D-arabinofuranosyl-E-5-(2-chlorovinyl)uracil (CV-ara-U) were tested for their anti-herpesviral activity in virus rating method, a plaque reduction method, and a virus yield reduction method, using human embryonic lung fibroblast (HEL-F) cells, At a concentration as low as 0.1 microgram/ml, both drugs exerted a marked inhibitory effect on the development of cytopathogenic effect induced by herpes simplex virus type 1 (HSV-1) infection and on the multiplication and plaque formation of HSV-1. Neither BV-ara-U nor CV-ara-U was significantly active against HSV type 2 (HSV-2). They scarcely inhibited growth of HEL-F cells, mouse L, and murine leukemia cells. Compared with 1-beta-D-arabinofuranosylthymine and 5-iodo-deoxyuridine, BV-ara-U and CV-ara-U were more than 10 times as active against HSV-1 and much less active against HSV-2. BV-ara-U was as active as E-5-(2-bromovinyl)-2'-deoxyuridine against HSV-1 and less inhibitory to growth of HEL-F cells. Cellular deoxyribonucleic acid synthesis was not significantly influenced by the new derivatives of arabinosyluracil, even at a concentration as high as 300 microgram/ml. The derivatives showed extremely marked inhibition of deoxyribonucleic acid synthesis in HSV-1-infected cells, whereas their inhibitory effect on deoxyribonucleic acid synthesis in HSV-2-infected cells was much lower than that in HSV-1-infected cells. These findings indicate that BV-ara-U and CV-ara-U are selectively inhibitory to HSV-1 multiplication.
 ...
PMID:Antiherpesviral and anticellular effects of 1-beta-D-arabinofuranosyl-E-5-(2-halogenovinyl) uracils. 626 82

The growth of herpes simplex virus (HSV) type 1 in human lymphoid cell lines, arrested at various stages of differentiation, was studied. The synthesis of viral DNA and antigens and the production of infectious virus were followed in null, B and T leukemia-lymphoma cell lines. It was found that while "nondifferentiated" null cells and cells differentiating along the B pathway, even at very early stages of differentiation, supported HSV growth, cell lines of T origin at all stages of differentiation were generally nonpermissive. The failure of T cells to support the growth of HSV did not result from inefficient adsorption to the host cells. However, viral DNA synthesis was not detected, and a significant reduction in the ability of synthesize HSV antigens was observed. It is suggested that the block in the growth cycle of the virus occurs at a stage after adsorption of the virion to the cells, but prior to synthesis of its DNA and proteins.
 ...
PMID:Interaction of Herpes simplex virus with human cell lines at various stages of lymphoid differentiation. 627 25

Twenty patients undergoing allogeneic bone marrow transplantation and 39 patients receiving remission induction chemotherapy for acute leukaemia were entered into a double blind, placebo controlled stratified trial of acyclovir prophylaxis against herpes group virus infections. Within the transplant group intravenous acyclovir 5 mg/kg twice daily given throughout the period of granulocytopenia completely prevented oropharyngeal herpes simplex virus infection compared with a 50% incidence in the placebo arm (p = 0.033). The acyclovir group also had fewer days of fever during the trial and a shorter duration of leukopenia, possibly because of the prevention of herpes simplex virus infections. There was a high incidence of herpes infections after the trial in patients who received either acyclovir or placebo. In the non-transplant group there was also a significant reduction of herpes simplex virus infection in the oropharynx and oesophagus (two out of 19 patients as compared with 10 out of 20; p = 0.018). Herpes simplex virus was isolated in the acyclovir arm within a day after starting the trial in one patient, and the other failure was due to a virus with reduced sensitivity to acyclovir in a patient who had had several previous courses of the drug. The incidence of herpes infections after stopping treatment was low. The influence of acyclovir on excretion of Epstein-Barr virus in saliva in either group was inconclusive. One patient (transplant group) developed a cytomegalovirus infection while receiving acyclovir. Acyclovir provides effective prophylaxis against oropharyngeal and oesophageal herpes simplex virus infection in severely immunocompromised seropositive (greater than or equal to 1/8) patients. In patients given bone marrow transplants this may have the additional benefit of reducing the time to recovery of an adequate blood count and the number of days of fever.
 ...
PMID:Acyclovir prophylaxis against herpes virus infections in severely immunocompromised patients: randomised double blind trial. 630 64

Two consecutive studies are reported. In study 1, 59 patients with acute leukaemia undergoing remission induction therapy or bone marrow transplantation were given either acyclovir (5 mg/kg) or placebo by intravenous infusion twice daily during the period of neutropenia. All patients were seropositive (greater than or equal to 1:8) for herpes simplex virus. Acyclovir provided total protection against herpes simplex virus infection in bone marrow transplant patients with 0/10 versus 5/10 infections in the placebo group (P = 0.033). For the remission induction therapy group 2/19 on acyclovir developed HSV versus 10/20 receiving placebo (P = 0.018). Only one episode of cytomegalovirus (CMV) infection was seen and this was in a patient on acyclovir. Epstein-Barr virus secretion studies were inconclusive. No varicella zoster virus (VZV) infections were seen. In Study 2, 20 consecutive HSV seropositive (greater than or equal to 1:8) bone marrow transplant recipients received oral acyclovir. Five (25%) developed HSV infections, one of which was in a non-compliant patient, who subsequently developed a fatal infection whilst receiving therapeutic (5 mg/kg 8 hourly) intravenous acyclovir for this HSV infection. Intravenous acyclovir is effective in preventing HSV infections in the immunocompromised host but it seems unlikely that CMV will be amenable to acyclovir in its present formulation.
 ...
PMID:Use of acyclovir for prophylaxis of herpes infections in severely immunocompromised patients. 631 94

Iodination of 1-(2,3,5-tri-O-acetyl-beta-D-arabinofuranosyl)uracil furnished the 5-iodo derivative (Ib), which, on treatment with (trimethylsilyl)acetylene in the presence of catalytic amounts of (Ph3P)2PdCl2/CuI and subsequent deblocking, afforded 1-beta-D-arabinofuranosyl-5-ethynyluracil (Ie). Condensation of the trimethylsilyl derivative of 5-(dibromovinyl)uracil with 3-O-acetyl-5-O-benzoyl-2-deoxy-2-azido-D-arabinofuranosyl chloride, followed by treatment with phenyllithium, gave 1-(2-deoxy-2-azido-beta-D-arabinofuranosyl)-5-ethynyluracil (IIb). Condensation of 3-O-acetyl-5-O-benzoyl-2-deoxy-2-fluoro-D-arabinofuranosyl bromide with the trimethylsilyl derivative of 5-ethynylcytosine and subsequent removal of the protecting groups furnished 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-ethynylcytosine (IIIb). The structural assignment for IIb and IIIb was made by NMR and ORD spectra. Compounds Ie and IIIb inhibited the growth of leukemia L-1210 cells in culture by 50% at concentrations of 1.7 X 10(-5) and 6 X 10(-5) M, respectively. In addition, Ie and IIIb inhibited the replication of herpes simplex virus type I by 90% at concentrations of 2.8 X 10(-5) and 5 X 10(-5) M, respectively. Compound IIb did not show any antileukemic or antiherpes activity.
 ...
PMID:Acetylenic nucleosides. 3. Synthesis and biological activities of some 5-ethynylpyrimidine nucleosides. 632 37

An outbreak of unexplained immune deficiency associated with opportunistic infection and Kaposi's sarcoma is occurring in the USA and other parts of the world. Affected individuals with what had come to be known as the acquired immune deficiency syndrome (AIDS) have a high mortality. Epidemiological features suggest the presence of a transmissable agent, but no responsible agent has yet been identified. Homosexual and bisexual men make up 75% of these affected individuals. Cytomegalovirus, Epstein Barr and herpes simplex viruses, organisms that commonly affect male homosexuals, may produce some features of AIDS. Individually or collectively, however, they can not account for the emergence of a previously unrecognized clinical syndrome. Hepatitis B is prevalent in patients with AIDS and may play a role as a co-factor in the disease. The properties of a number of other known viruses may provide a model for the pathogenesis of some features of the AIDS immunodeficiency. Newly described simian acquired immune deficiency syndrome (SAIDS) is the best available animal model. In man, the retrovirus, human T-cell leukemia virus (HTLV) may play a role in AIDS. However, HTLV or any other known virus cannot yet be assumed to cause AIDS. It is likely that an as yet unrecognized agent is the key causative agent of AIDS.
 ...
PMID:Searching for the cause of the acquired immune deficiency syndrome. 632 76

A recombinant plasmid containing the herpes simplex virus thymidine kinase (tk) gene, flanked on one side by two murine immunoglobulin heavy chain diversity (D) elements and on the other by two murine immunoglobulin heavy chain joining (JH) elements, was introduced into a tk- variant of a pre-B cell line transformed by Abelson murine leukemia virus. The four possible site-specific joining events between the D and JH segments within the integrated construct occurred frequently during passage of the cloned line under nonselective conditions, and deletion of the internal tk gene as a result of these joining events was, by far, the predominant mechanism of resistance to BUdR within this line. These studies demonstrate that a precise chromosomal location is not essential for the assembly of D and JH elements and provide a model system for mechanistic and genetic studies of this recombination process.
 ...
PMID:Site-specific recombination between immunoglobulin D and JH segments that were introduced into the genome of a murine pre-B cell line. 632 46

A series of iron chelating agents including the bacterial siderophores, parabactin and bis-N1,N8(2,3 dihydroxybenzoyl )spermidine, and four related compounds were synthesized and tested biologically. They were found: (a) to inhibit growth of cultured L1210 leukemia cells at IC50 values of 2-14 microM, (b) to inhibit replication of the DNA virus, herpes simplex type I, in monkey kidney cells at IC50 values of 0.4 microM ( parabactin ) to 55 microM, and (c) to be inactive against the RNA virus, vesicular stomatitis, at concentrations up to 1 mM. All effects were fully preventable by exogenous Fe (III). The activities correlated generally with the iron formation constants (10(36) to 10(48) moles/1) and more specifically with the lipophilicity of the compounds. The data suggest inhibition of DNA (but not RNA) synthesis by interference with the iron-containing enzyme, ribonucleotide reductase.
 ...
PMID:Antineoplastic and antiherpetic activity of spermidine catecholamide iron chelators. 633 31

Bone marrow transplantation is now an accepted component in the overall therapy of acute and chronic (myeloid) leukaemia for some selected patients. Some of the obstacles to success have been partially overcome. Many advances in supportive care have been made. Pneumocystis carinii and herpes simplex infections are preventable. Effective decontamination of the gastrointestinal tract for bacteria and fungi is now readily achievable and may have reduced the risk of serious systemic infections. New antibiotics which, in combination, are effective in life-threatening infections are under study. Recent developments in the prevention or amelioration of graft versus host disease (GvHD) have included T lymphocyte depletion in the donor marrow and the use of the fungal polypeptide cyclosporin A. Less than 10% of patients would now be expected to succumb to this complication. Outstanding problems remaining to be resolved are the improvement in the antileukaemic conditioning prior to transplantation and the prevention or treatment of cytomegalovirus infection in the seropositive recipient. This infection can cause pneumonitis and is currently the single most frequent transplant related cause of mortality.
 ...
PMID:A review of the current status and techniques of allogeneic bone marrow transplantation for treatment of leukaemia. 635 92

That acyclovir is effective therapeutically in herpes simplex virus (HSV) and herpes zoster (VZV) infections in immunocompromised patients has been established [13]. This paper reviews our subsequent studies in prophylaxis of herpes group infections in a high risk group of patients suffering from acute leukaemia. In study 1 we randomised HSV seropositive (greater than or equal to 1:8) patients to receive intravenous acyclovir or placebo. In this stratified study bone marrow transplant (BMT) recipients were completely protected from HSV infections by acyclovir compared with a 50% failure rate for those on placebo. There was significant protection also in the non-BMT group [8]. In study 2 oral acyclovir prophylaxis failed to provide complete protection in BMT recipients despite the achievement of apparently adequate blood levels. In study 1 the secretion of EBV in saliva before and during the trial gave inconclusive results. In each of the first two studies one patient on "active" acyclovir developed a cytomegalovirus (CMV) infection. Thus, at the dosage of drug used, prophylaxis of CMV was unsuccessful suggesting that claims of therapeutic efficacy are unlikely to be supported in controlled trials. Study 3 is current and concerns the pharmacokinetics of an acyclovir prodrug (BW 134U) taken by mouth. This drug is near 100% absorbed and achieves approximately twice the level of active acyclovir in vivo, following conversion by adenosine deaminase (ADA), in normal volunteers.
 ...
PMID:Studies in the prophylaxis of herpes infections in severely immunocompromised patients using acyclovir. 636 88


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>